EQ
Equillium, Inc. NASDAQ Listed Oct 12, 2018$2.14
Mkt Cap $76.0M
52w Low $0.27
77.0% of range
52w High $2.70
50d MA $2.00
200d MA $1.46
P/E (TTM)
-5.3x
EV/EBITDA
-4.8x
P/B
6.7x
Debt/Equity
0.0x
ROE
-78.3%
P/FCF
-6.2x
RSI (14)
—
ATR (14)
—
Beta
1.74
50d MA
$2.00
200d MA
$1.46
Avg Volume
511.1K
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
2223 Avenida De La Playa · La Jolla, CA 92037 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.07 | -0.04 | +42.9% | 2.06 | -3.4% | +0.0% | -8.7% | -6.9% | +14.3% | +2.0% | — |
| Nov 13, 2025 | AMC | -0.14 | -0.06 | +57.1% | 0.84 | +0.0% | +23.8% | +1.0% | -4.8% | +1.0% | +0.0% | — |
| Aug 14, 2025 | AMC | -0.14 | -0.16 | -14.3% | 0.98 | +2.0% | +16.3% | +17.5% | -10.4% | -5.0% | +36.8% | — |
| May 14, 2025 | AMC | -0.23 | -0.24 | -4.3% | 0.37 | +12.1% | +4.5% | -4.1% | +2.7% | +0.3% | -0.1% | — |
| Mar 27, 2025 | AMC | -0.22 | -0.16 | +27.3% | 0.49 | -7.4% | -16.9% | -3.2% | +28.4% | -2.5% | -4.5% | — |
| Nov 13, 2024 | AMC | -0.26 | -0.00 | +99.9% | 0.78 | -2.6% | -12.3% | +3.7% | -4.0% | +2.8% | +2.6% | — |
| Aug 8, 2024 | AMC | -0.15 | 0.01 | +106.7% | 0.71 | +6.9% | -1.5% | +2.9% | +1.4% | +9.5% | +1.4% | — |
| May 9, 2024 | AMC | -0.17 | -0.08 | +52.9% | 1.80 | +5.0% | -15.0% | +0.7% | +0.0% | +0.0% | +0.0% | — |
| Mar 25, 2024 | AMC | -0.17 | -0.07 | +58.8% | 2.44 | -7.4% | -15.6% | +0.0% | +12.1% | -8.7% | +3.3% | — |
| Nov 8, 2023 | AMC | -0.16 | -0.11 | +31.2% | 0.50 | +5.2% | -4.7% | +4.0% | +0.9% | -1.6% | +1.6% | — |
| Aug 9, 2023 | AMC | -0.19 | -0.10 | +47.4% | 0.77 | +5.2% | +3.9% | +1.2% | -2.5% | -6.3% | +10.8% | — |
| May 11, 2023 | AMC | -0.20 | -0.11 | +45.0% | 0.57 | -1.8% | +1.8% | +17.2% | -11.8% | -3.3% | +1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23 | Oppenheimer | Initiates | Outperform | $7 | $2.33 | $2.40 | +3.0% | -6.9% | -0.5% | -5.6% | +0.5% | +1.5% |
| Apr 17 | Roth Capital | Maintains | Buy → Buy | — | $1.98 | $2.06 | +4.0% | +3.5% | -2.0% | +7.0% | +8.4% | -6.9% |
| Mar 28 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $0.49 | $0.45 | -7.4% | -16.9% | -3.2% | +28.4% | -2.5% | -4.5% |
| Nov 1 | Jones Trading | Downgrade | Buy → Hold | — | $0.86 | $0.86 | +0.0% | -3.6% | -9.6% | -0.7% | +0.9% | +1.9% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.79 | $0.79 | +0.6% | -0.6% | +5.9% | -0.4% | +14.3% | +16.0% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $0.95 | -10.4% | -19.1% | +4.6% | -10.7% | -11.7% | +2.8% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.55 | +0.6% | +1.3% | -0.6% | -2.6% | -5.3% | -2.1% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.11 | $2.11 | +0.0% | +3.3% | +6.9% | -4.7% | -4.1% | -9.9% |
| Dec 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.66 | $0.65 | -1.1% | -3.5% | +2.7% | +4.4% | +6.3% | +1.6% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.50 | $0.50 | +0.1% | +0.9% | -1.6% | +1.6% | +0.0% | +0.0% |
| Aug 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $0.81 | $0.81 | +0.0% | -2.5% | -6.3% | +10.8% | +2.4% | +0.0% |
| Aug 14 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $0.81 | $0.81 | +0.0% | -2.5% | -6.3% | +10.8% | +2.4% | +0.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.81 | $0.81 | +0.0% | -2.5% | -6.3% | +10.8% | +2.4% | +0.0% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.58 | $0.60 | +3.4% | +17.2% | -11.8% | -3.3% | +1.7% | +5.1% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.62 | $0.64 | +3.2% | -3.2% | -6.7% | +0.0% | -3.6% | -1.9% |
| Mar 24 | Stifel | Maintains | Buy → Buy | — | $0.65 | $0.65 | +0.0% | +12.3% | -2.7% | +1.4% | -1.4% | +1.4% |
| Feb 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $1.23 | $1.25 | +1.6% | +0.8% | -10.5% | +2.7% | -0.9% | +3.5% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.93 | $2.23 | +15.5% | +22.8% | -5.9% | +2.7% | -3.1% | +1.8% |
| Sep 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.41 | $2.40 | -0.4% | -7.9% | +2.7% | +0.0% | -2.2% | -5.8% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.30 | $3.52 | +6.7% | -0.3% | -0.9% | -8.3% | +0.3% | +5.7% |
| Jan 5 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.60 | $3.56 | -1.1% | -5.3% | +1.8% | -0.3% | +0.3% | +3.2% |
| Sep 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.40 | $5.53 | +2.4% | +8.7% | +1.0% | +7.6% | -5.8% | +8.5% |
| Mar 3 | JonesTrading | Maintains | Buy → Buy | — | $7.20 | $7.44 | +3.3% | -0.1% | -7.0% | +0.9% | -0.1% | +13.6% |
| Nov 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.92 | $5.04 | +2.4% | +5.7% | -4.6% | +1.6% | -2.2% | -0.6% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.84 | $6.85 | +0.1% | +0.6% | -2.3% | +4.8% | -2.6% | -12.8% |
| Jul 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.50 | $19.12 | -27.8% | -47.2% | +24.0% | -14.8% | -6.2% | -1.6% |
| Jul 2 | H.C. Wainwright | Maintains | Buy → Buy | — | $5.44 | $6.53 | +20.0% | +2.9% | -1.6% | -0.2% | +0.0% | +0.0% |
| Nov 6 | Jefferies | Maintains | Buy → Buy | — | $16.34 | $15.11 | -7.5% | +3.9% | +0.7% | -0.6% | -2.9% | -5.5% |
| Nov 6 | Stifel Nicolaus | Maintains | Buy → Buy | — | $16.34 | $15.11 | -7.5% | +3.9% | +0.7% | -0.6% | -2.9% | -5.5% |
No insider trades available.
8-K
Unknown — 8-K Filing
Equillium secured funding through 2029 and initiated an EQ504 clinical trial, providing runway for value-creating development, though mid-stage biotech risks remain significant for investors.
Mar 25
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
EQ issued pre-funded warrants with cashless exercise options and ownership caps, diluting existing shareholders while raising capital without immediate cash burden on warrant holders.
Mar 13
Data updated apr 25, 2026 7:28am
· Source: massive.com